Abstract C188: A phase 1 study of RXDX-105, an oral RET, BRAF and EGFR tyrosine kinase inhibitor, in patients with advanced or metastatic cancers

Journal article

Peer reviewed

Ding Wang, Manish Patel, Marwan Fakih, A. Craig Lockhart, Anthony J Olszanski, Rupal Patel, Peter D Brown, Jennifer W Oliver and Pratik S Multani

Molecular cancer therapeutics, Vol.14(12 Supplement 2), pp.C188-C188

2015-12

Metrics

12 Record Views

Title: Abstract C188: A phase 1 study of RXDX-105, an oral RET, BRAF and EGFR tyrosine kinase inhibitor, in patients with advanced or metastatic cancers
Creators: Ding Wang
Manish Patel
Marwan Fakih
A. Craig Lockhart
Anthony J Olszanski
Rupal Patel
Peter D Brown
Jennifer W Oliver
Pratik S Multani
Publication Details: Molecular cancer therapeutics, Vol.14(12 Supplement 2), pp.C188-C188
Academic Unit: Miller School of Medicine
Language: English
Resource Type: Journal article
Record Identifier: 991031598414302976